Comparison · NCT01595529-bd51a0eb
Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Standard Course Treatment vs Short Course Treatment: Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population. Trial comparisons, record NCT01595529-bd51a0eb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01595529-bd51a0eb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0357 | 0.0201 | 0.0628 | wilson | |
| Risk in group 2 | 0.0924 | 0.0651 | 0.129 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0566 | -0.0969 | -0.0182 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.387 | 0.197 | 0.76 | log | |
| Odds ratio, group 1 over group 2 | 0.364 | 0.178 | 0.742 | log | |
| Number needed to treat, for one fewer participant with the outcome on Standard Course Treatment than on Short Course Treatment | 17.7 | 10.3 | 55 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Standard Course Treatment | 5 days of active therapy to match the physician-initiated therapy, Trimethoprim sulfamethoxazole, Cefixime or Cefdinir or Cephalexin (subjects originally receiving Cefdinir will receive Cefixime)~Cefixime: Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.~Cephalexin: Cephalexin 50mg/kg/day in 3 divided doses~Trimethoprim/Sulfamethoxazole: 8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day. | 11 | 308 | OG000 |
| Group 2 | Short Course Treatment | 5 days of placebo treatment to match physician-initiated therapy~Placebo: Placebo to match the other four active treatments | 29 | 314 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.
- Description
Asymptomatic Bacteriuria is defined in any SCOUT subject by:~1. Absence of symptoms attributable to UTI including fever AND/OR the following:~ * Symptoms for all children (ages two months to 10 years):~ * fever (a documented temperature of at least 100.4 °F OR 38°C measured anywhere on the body)~ * dysuria~ * Additional symptoms for children \> 2 years of age:~ * suprapubic, abdominal, or flank pain or tenderness OR~ * urinary urgency, frequency, or hesitancy (defined as an increase in these symptoms from pre-diagnosis conditions)~ * Additional symptoms for children = 2 months to 2 years of age:~ * poor feeding OR~ * vomiting AND~2. A positive urine culture~ * 5 x 104 CFU/mL (catheterized or suprapubic aspiration urine specimen) OR~ * \>105 CFU/mL (clean void specimen).
- Time frame
- Day 11 through Day 14
- Population
Per-protocol Population (PP): The enrolled subjects who were adherent to their assigned study regimen and completed more than 80% of the prescribed dose between Day 6 and Day 10 (per-protocol population).
Source ClinicalTrials.gov
Trial
- Title
- The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"
- NCT number
- NCT01595529
- Phases
- PHASE2
- Conditions
- Urinary Tract Infection
- Interventions
- Cefixime, Cephalexin, Placebo, Trimethoprim/Sulfamethoxazole
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2020-07-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01595529?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01595529-bd51a0eb